Antimicrobial Susceptibility - Nocardia
Also known as: MA NOC
Use
This test determines the in vitro susceptibility of Nocardia spp. and other aerobic actinomycetes to a range of antimicrobial agents. It is crucial for selecting appropriate antimicrobial therapy for infections caused by these organisms. Susceptibility is interpreted based on CLSI guidelines using broth microdilution and custom-made MIC panels. The agents tested include amikacin, ciprofloxacin, clarithromycin, doxycycline, imipenem, linezolid, moxifloxacin, tigecycline, tobramycin, and trimethoprim/sulfamethoxazole.
Special Instructions
Selective reporting is applied based on the organism identified. Samples must be actively growing Nocardia organisms in pure culture. It is essential to transport the sample in a sealed container on an agar slant. An additional processing fee applies for organisms not submitted in pure culture, and species identification may incur extra charges if not provided.
Limitations
Mixed cultures and nonviable organisms are unacceptable. Specimens submitted in mixed culture may lead to the additional processing fee. The susceptibility results are limited to the panel of antibiotics listed, and the interpretation is dependent on the CLSI guidelines which may change over time. Errors in organism identification can result in inappropriate susceptibility reporting.
New York Approved
Methodology
Culture-based
Biomarkers
LOINC Codes
- 29576-6
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Cultured Cells
Volume
Not provided
Minimum Volume
Not provided
Container
Sealed container on agar slant
Collection Instructions
Transport in a sealed container with isolate in pure culture on agar slant.
Causes for Rejection
Mixed cultures or nonviable organisms.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 month |
| Refrigerated | 2 weeks |
| Frozen | Unacceptable |